next officials testifying on the use of biometrics and its impact on ibc. they are asked about the use of facial recognition technology and agassi risk. the hearing before the house of committee on investigations and oversight. it is just under an hour and a half. today our focus will be on how technological solutions can secure our argosy while allowing us to enjoy the benefits of biometric tools. biometric ibc and technologies can and should be implemented along with biometric technologies. so-called be pets and they can be impacted implemented at the improving the precision of collection to ensure they are not using features that are not necessary for use. they can insert, for example, austro patients on data collected. unintended uses. a technique called protection can ensure that one system biometric information is encrypted such that it cannot be read by another system. for example, someone s image obtained from the security systems at a doctor or psychiatri
near east palestine ohio and the ensuing chemical spill and controlled burned. it is the latest incident to put federal and state disaster response. it also matters to those most affected by these crises, how quickly local, state and federal officials respond. what immediate aid and solutions they offer, and in the ever put times, who shows up to help? good morning. it is washington journal from thursday, february 23, 2023. we will ask you about your trust in government disaster response. the lines to use to weigh in, 202 7488 thousand for eastern time zones, (202) 748-8001 for mountain pacific. (202) 748-8003 for texting. you can send us a message on facebook and twitter and instagram. the government response to disasters. there is some data that was done in the wake of the east palestine spill. the train derailment there as we said, nearly three weeks ago. we will also hear from some of those site, putting the former president donald trump. the transfer tatian transport
Over seven weeks in the criminal fraud trial of Elizabeth Holmes, prosecutors have shown that her startup Theranos Inc. took shortcuts when claims about its revolutionary blood-testing technology became scientifically unfeasible and that employees feared retaliation for raising concerns.